Value
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.1 |
| P/S | 6.7 |
| EV/EBITDA | 2.6 |
| Fwd P/E | 7.8 |
| PEG | 6.1 |
| Analyst target | 7.5 |
- ▸Forward P/E: 15.5x
- ▸PEG: 1.22
HQY · Why this verdict
Why HealthEquity (HQY) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A high-quality health benefits platform with four consecutive earnings beats and free cash flow running at 161% of net income is temporarily weighed down by a confirmed price downtrend and a death cross; roughly 20% room to the analyst-consensus target and a 2.3-to-1 favorable risk/reward suggest the setup can reward patience once momentum recovers, though the technical block and single-product concentration risk make the near-term path uncertain.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow running at 161% of net income, combined with 17% operating margins and a perfect Piotroski F-Score of 9 out of 9, signals a financially sound business with strong cash generation that substantially exceeds reported earnings — a hallmark of durable quality. Quality breakdown | Free cash flow continues to exceed net income by more than 100% over the next two reported annual periods, confirming durable cash conversion rather than a one-period benefit. | →Stable |
| CounterA cash-conversion ratio well above 100% can reflect favorable working-capital timing or one-time items; if revenue growth slows and mix shifts, free cash flow coverage could compress meaningfully and remove a key quality differentiator. | ||
The company has delivered four consecutive quarterly earnings beats, averaging roughly 11% above consensus across each of those quarters, demonstrating a sustained pattern of delivering above expectations. Earnings | The beat streak extends through the next reported quarter (due roughly 77 days out), with an earnings surprise of at least 5% above consensus. | →Stable |
| CounterA four-quarter beat streak can reflect guidance set conservatively after a prior reset rather than structural earnings strength; the next earnings event may be the first inflection point where the pattern breaks if revenue growth moderates. | ||
The stock is in a confirmed downtrend — below the 200-day moving average with the trend declining at roughly 1.1% per month — and a death cross is currently in force, creating a technical headwind that tends to attract selling pressure and keeps momentum-oriented investors on the sidelines. Engine gate (failed) | Price crosses back above the 200-day moving average and holds above for at least 5 consecutive sessions, signaling trend reversal and removing the primary technical block. | →Stable |
| CounterHigh-quality businesses frequently exhibit extended dislocations between price and fundamental value; the downtrend may persist for multiple additional months before reversing, particularly if broader market sentiment stays cautious. | ||
With roughly 20% room to the analyst-consensus target of $104 and a risk/reward of approximately 2.3-to-1 in your favor, the stock offers an asymmetric setup where upside materially outweighs near-term downside — a geometry that typically rewards patient holders as fundamental quality reasserts itself. Price targets | Price advances to within 5% of the $104 analyst target within 12 months as fundamentals remain intact and the technical headwind fades. | →Stable |
| CounterA favorable risk/reward ratio assumes the analyst target is anchored to realistic fundamentals; if earnings growth slows, targets may be cut, compressing the apparent upside before the stock ever reaches the current consensus level. | ||
Revenues are concentrated in health savings accounts and consumer-directed benefit programs, meaning any adverse regulatory action on contribution limits or employer incentive structures could impair the core growth engine with limited offset from other product lines. Bear case | Non-HSA product revenues grow faster than the overall business for 4 consecutive quarters, demonstrating that the company is reducing single-vertical dependency. | →Stable |
| CounterConcentration in a single regulated product category may reflect deliberate focus on a structurally growing market rather than unmanaged risk; the HSA market has demonstrated resilience across legislative cycles. | ||
Free cash flow running at 161% of net income, combined with 17% operating margins and a perfect Piotroski F-Score of 9 out of 9, signals a financially sound business with strong cash generation that substantially exceeds reported earnings — a hallmark of durable quality.
→StableQuality breakdown
- Expectation
- Free cash flow continues to exceed net income by more than 100% over the next two reported annual periods, confirming durable cash conversion rather than a one-period benefit.
CounterA cash-conversion ratio well above 100% can reflect favorable working-capital timing or one-time items; if revenue growth slows and mix shifts, free cash flow coverage could compress meaningfully and remove a key quality differentiator.
The company has delivered four consecutive quarterly earnings beats, averaging roughly 11% above consensus across each of those quarters, demonstrating a sustained pattern of delivering above expectations.
→StableEarnings
- Expectation
- The beat streak extends through the next reported quarter (due roughly 77 days out), with an earnings surprise of at least 5% above consensus.
CounterA four-quarter beat streak can reflect guidance set conservatively after a prior reset rather than structural earnings strength; the next earnings event may be the first inflection point where the pattern breaks if revenue growth moderates.
The stock is in a confirmed downtrend — below the 200-day moving average with the trend declining at roughly 1.1% per month — and a death cross is currently in force, creating a technical headwind that tends to attract selling pressure and keeps momentum-oriented investors on the sidelines.
→StableEngine gate (failed)
- Expectation
- Price crosses back above the 200-day moving average and holds above for at least 5 consecutive sessions, signaling trend reversal and removing the primary technical block.
CounterHigh-quality businesses frequently exhibit extended dislocations between price and fundamental value; the downtrend may persist for multiple additional months before reversing, particularly if broader market sentiment stays cautious.
With roughly 20% room to the analyst-consensus target of $104 and a risk/reward of approximately 2.3-to-1 in your favor, the stock offers an asymmetric setup where upside materially outweighs near-term downside — a geometry that typically rewards patient holders as fundamental quality reasserts itself.
→StablePrice targets
- Expectation
- Price advances to within 5% of the $104 analyst target within 12 months as fundamentals remain intact and the technical headwind fades.
CounterA favorable risk/reward ratio assumes the analyst target is anchored to realistic fundamentals; if earnings growth slows, targets may be cut, compressing the apparent upside before the stock ever reaches the current consensus level.
Revenues are concentrated in health savings accounts and consumer-directed benefit programs, meaning any adverse regulatory action on contribution limits or employer incentive structures could impair the core growth engine with limited offset from other product lines.
→StableBear case
- Expectation
- Non-HSA product revenues grow faster than the overall business for 4 consecutive quarters, demonstrating that the company is reducing single-vertical dependency.
CounterConcentration in a single regulated product category may reflect deliberate focus on a structurally growing market rather than unmanaged risk; the HSA market has demonstrated resilience across legislative cycles.
Per-dimension breakdown
Quality
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.7 |
| ROA | 4.3 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 8.6 |
| Current ratio | 9.6 |
| FCF quality | 10.0 |
| Moat | 6.5 |
| Rule of 40 | 5.5 |
| Piotroski F | 10.0 |
- ▸Strong margins: 17%
- ▸Excellent cash conversion: 161% FCF/NI
- ▸Strong Piotroski F-Score: 9/9
- ▸High-quality business
Growth
6.6/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.3 |
| EPS growth | 8.9 |
Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 1.5 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 9.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 37%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Insider selling (low materiality) — $1,193,000 (0.017% of mkt cap)
Peer rank
3.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.6 |
| quality rank | 7.3 |
| growth rank | 2.5 |
Technical
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.4 |
| support resistance | 9.7 |
| 52w position | 4.5 |
Risk (lower is worse)
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.7 |
| days to cover | 6.5 |
| volatility | 5.5 |
| put call | 0.0 |
| implied vol | 5.2 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 8.1 |
- ▸Elevated put/call: 2.93
- ▸Above max pain $65
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 8.2 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (6)
- ASYMMETRY:4.1>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:68d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.2<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
4.12
Upside
+23.1%
Downside
5.6%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeTEMP_HEADWIND — High quality (7.8) with weak momentum (3.2)
SuitabilityMODERATE — Balanced profile
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: ASYMMETRY:4.1>=1.5. Top dim: Quality at 7.8; weakest: Momentum at 3.2. No conviction either direction.
The strongest dimensions are Quality at 7.8, Technical at 7.5, and Sentiment at 7.2; the weakest are Momentum at 3.2, Peer rank at 3.6, and Insider at 5.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 4.12 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has delivered four consecutive quarterly earnings beats, averaging roughly 11% above consensus across each of those quarters, demonstrating a sustained pattern of delivering above expectations.
Trip ifEPS surprise falls below 0% for 2 consecutive reported quarters.
- P2Free cash flow running at 161% of net income, combined with 17% operating margins and a perfect Piotroski F-Score of 9 out of 9, signals a financially sound business with strong cash generation that substantially exceeds reported earnings — a hallmark of durable quality.
Trip ifFree cash flow falls below 100% of net income for 2 consecutive reported periods.
- P3The stock is in a confirmed downtrend — below the 200-day moving average with the trend declining at roughly 1.1% per month — and a death cross is currently in force, creating a technical headwind that tends to attract selling pressure and keeps momentum-oriented investors on the sidelines.
Trip ifPrice crosses above the 200-day moving average and holds above for 5 consecutive trading sessions.
- P4With roughly 20% room to the analyst-consensus target of $104 and a risk/reward of approximately 2.3-to-1 in your favor, the stock offers an asymmetric setup where upside materially outweighs near-term downside — a geometry that typically rewards patient holders as fundamental quality reasserts itself.
Trip ifUpside to the $104.01 analyst target compresses below 5% without a corresponding upward revision to the target.
- P5Revenues are concentrated in health savings accounts and consumer-directed benefit programs, meaning any adverse regulatory action on contribution limits or employer incentive structures could impair the core growth engine with limited offset from other product lines.
Trip ifNon-HSA product revenues represent less than 5% of total reported revenue for 2 consecutive quarters, confirming that concentration is increasing rather than decreasing.